[1]Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors[J]. Nat Rev Mol Cell Biol, 2005, 6(11):827-837. [2]Matallanas D, Birtwistle M, Romano D, et al. Raf family kinases:old dogs have learned new tricks[J]. Genes Cancer, 2011, 2(3):232-260. [3]Montagut C, Settleman J. Targeting the Raf-MEK-ERK pathway in cancer therapy[J]. Cancer Lett, 2009, 283(2):125-134. [4]Leicht DT, Balan V, Kaplun A, et al. Raf kinases:function, regulation and role in human cancer[J]. Biochim Biophys Acta, 2007, 1773(8):1196-1212. [5]Osborne JK, Zaganjor E, Cobb MH. Signal control through Raf:in sickness and in health[J]. Cell Res, 2012, 22(1):14-22. [6]An S, Yang Y, Ward R, et al. A-Raf:A new star of the family of raf kinases[J]. Crit Rev Biochem Mol Biol, 2015, 50(6):520-530. [7]Imielinski M, Gredulich H, Kaplan B. Oncogenic and sorafenib-sensitive A-Raf mutations in lung adenocarcinoma[J]. J Clin Invest, 2014, 124(4):1582-1586. [8]Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating A-Raf mutations in Langerhans cell histiocytosis[J]. Blood, 2014, 123(20):3152-3155. [9]Olson JM, Hallahan AR. P38MAPK kinase:a convergence pointin cancer therapy[J]. Trends Mol Med, 2004, 10(3):125-129. [10]Osbome JK, Zaganjor E, Cobb HM. Signal control through Raf:in sickness and in health[J]. Cell Res, 2012, 22(1):14-22. [11]Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases[J]. Genes Cancer, 2011, 2(3):344-358. [12]Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy[J]. Expert Opin Ther Targets, 2012, 16(1):103-119. [13]Beeram M, Patnaik A, Rowinsky EK. Raf:a strategic target for therapeutic development against cancer[J]. J Clin Oncol, 2005, 23(27):6771-6779. [14]Kim DH, Sim T. Novel small molecule Raf kinase inhibitors for targeted cancer therapeutics[J]. Arch Pharm Res, 2012, 35(4):605-615. [15]Martin-Liberal J, Larkin J. New RAF kinase inhibitors in cancer therapy[J]. Expert Opin Pharmacother, 2014, 15(9):1235-1245. [16]邹平, 何涛, 陈颢, 等. 细胞衰老过程中JNK、p38和Akt的活性变化[J]. 中国生物化学与分子生物学报, 2006, 22(7):571-574. [17]Scheid MP, Schubert KM, Duronio V. Regulation of bad phosphorylation and association with Bcl-x(L)by the MAPK/ERK kinase[J]. J Biol Chem, 1999, 274(43):31108-31113. [18]Rauch J, Moran-Jones K, Albrecht V, et al. c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway[J]. Cancer Res, 2011, 71(13):4664-4674. [19]Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma[J]. J Clin Invest, 2014, 124(4):1582-1586. [20]Mooz J, Oberoi-Khanuja TK, Harms GS, et al. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration[J]. Sci Signal, 2014, 7(337):ra73. |